However, these values are lower than the 47% rate in cancer cell lines and 67% in colon carcinoma patient samples that had CN amplification of MET and FAM3C. The main reason for the differences observed between database, cell lines and patient samples are different cut-off points. This evidence concerns the gene FAM3C and colon carcinoma.